Results 71 to 80 of about 27,792 (251)

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science

Clinical Pharmacology &Therapeutics, EarlyView.
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human‐relevant alternatives to traditional preclinical models. This mini‐review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS).
Ksenia Blinova, Kimberly Chiu, Anik Chaturbedi, Jahan Cooper, Tromondae K. Feaster, Paula L. Hyland, Lidiya Stavitskaya, Wendy W. Wu, Jeffry Florian, Rodney Rouse   +9 more
wiley   +1 more source

CYP2C19 Haplotype Translator

, 2021
The translator included here was developed in the Aitchison lab to identify common haplotypes of the CYP2C19 gene, including: CYP2C19*2-*10, and *17.
Vasyl Yavorskyy (11600269), Katherine Aitchison (11598011)   +1 more
core   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Role of CYP2C19 polymorphisms in short-term rabeprazole-based triple therapy- Implication of PK/PD correlation

, 2010
簡介子幫浦為主的三合一療法為目前幽門螺旋桿菌的標準療法之一，一般建議的療程為7~14天；縮短的三合一療法雖可以降低醫療支出、減少副作用、增進病人服藥順服性，但因為到目前為止的研究結果分歧，故仍未被建議使用於治療中。Rabeprazole是質子幫浦抑制劑中效果較強，也較不受到代謝酵素CYP2C19基因型影響的一個藥物，然而，現今已證實，rabeprazole藥動、藥效特性仍受到CYP2C19基因型的影響，因此，CYP2C19緩慢代謝者是否可因此得到較好的治療成效 ...
楊喻帆, Yang, Yu-Fan
core  

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Pharmacokinetic- Pharmacodynamic Analysis of the Role of Cyp2c19 Genotypes in Short-Term Rabeprazole-Based Triple Therapy against Helicobacter Pylori

, 2011
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT center dot Asians have a higher percentage of CYP2C19 poor metabolizers (PMs) and a high percentage of Helicobacter pylori infection compared with Whites.
YANG, JYH-CHIN;YANG, YU-FAN;UANG, YOW-SHIENG;LIN, CHUN-JUNG;WANG, TEH-HONG, 楊智欽;楊喻帆;汪佑襄;林君榮;王德宏   +1 more
core  

The gut microbiome and drug‐resistant epilepsy: Microbiome–antiseizure medication interactions and implications for pharmacoresistance

Epilepsia Open, EarlyView.
Abstract Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and represents a major unmet clinical need. While traditional hypotheses of pharmacoresistance have focused on alterations in drug targets, efflux transporter overexpression, and intrinsic disease severity, the gut microbiome has recently emerged as a ...
Khaled Zammar, Majd A. AbuAlrob, Musab Ali, Simona Lattanzi, Boulenouar Mesraoua   +4 more
wiley   +1 more source

Plant‐Derived Extracts Disrupt Biofilm Formation and Quorum Sensing in Yersinia enterocolitica: Insights From GC‐MS and Molecular Docking

Food Chemistry International, EarlyView.
The graphical abstract represents how natural plant products that preferentially target the specific receptors of quorum sensing could be developed to combat biofilms linked to Yersinia enterocolitica using the potent abilities of protein–ligand complexes with high docking scores.
Rajendran Thomas, Songeeta Singha, Devarshi Bharadwaj, Abinash Kumar, Dolly Sharma, Sadhana Ojha, Hirakjyoti Das, Vivek Kumar Gupta   +7 more
wiley   +1 more source

METTL3-mediated methylation of CYP2C19 mRNA may aggravate clopidogrel resistance in ischemic stroke patients

Open Medicine
N6-methyladenosine (m6A) is the most frequently occurring interior modification in eukaryotic messenger RNA (mRNA), and abnormal mRNA modifications can affect many biological processes.
Tan Quandan, Yang Le, Yuan Shanshan, Zheng Danni, Lin Yapeng, Chen Kejie, He Ying, Chen Shuntian, Hao Junli, Dai Jin, He Song, Mao Fengkai, Leng Xinyi, Jiang Haisong, Yang Jie   +14 more
doaj   +1 more source

A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry

, 1998
CYP2C19 (S-mephenytoin hydroxylase) is a polymorphically expressed enzyme. Currently, two defective alleles are known - CYP2C19*2 and CYP2C19*3. The authors have developed an oligonucleotide ligation assay to detect these two alleles. This assay combines
Hansen, Torben Stiig, Brøsen, Kim, Hørder, Mogens, Bathum, Lise   +3 more
core   +1 more source